Renaissance Capital logo

BBTX News

Renaissance Capital’s October IPO Market Update

Bambusa Therapeutics logo

Eight IPOs raised a combined $1.2 billion in October, joined by one direct listing. Activity was well below the month’s 10-year historical average (22 IPOs, $5.1B). Six IPOs raised $100 million or more. With AI stocks under pressure in recent weeks,...read more

US IPO Weekly Recap: Anthropic files for potentially record-breaking IPO

ANT

Three IPOs, one direct listing, and two SPACs priced during a challenging week for growth stocks. However, the week’s most notable news came from Anthropic (ANT), which filed its long awaited S-1 on Monday for an IPO that could be the largest ever. ...read more

Immunology and inflammation biotech Bambusa Therapeutics prices upsized IPO at $16 midpoint

Bambusa Therapeutics logo

Bambusa Therapeutics, a Phase 2 biotech developing bispecific antibodies for inflammatory diseases, raised $169 million by offering 10.6 million shares at $16, within the $15 to $17 range. At pricing, the company commands a fully diluted market value of $856...read more

Immunology and inflammation biotech Bambusa Therapeutics sets terms for $150 million IPO

Bambusa Therapeutics logo

Bambusa Therapeutics, a Phase 2 biotech developing bispecific antibodies for inflammatory diseases, announced terms for its IPO on Monday. The Boston, MA-based company plans to raise $150 million by offering 9.4 million shares at a price range of $15 to $17....read more